Faculty Opinions recommendation of Disease activity in eosinophilic esophagitis is associated with impaired esophageal barrier integrity.

Author(s):  
Marc Rothenberg
2017 ◽  
Vol 313 (3) ◽  
pp. G230-G238 ◽  
Author(s):  
Marijn J. Warners ◽  
Bram D. van Rhijn ◽  
Joanne Verheij ◽  
Andreas J. P. M. Smout ◽  
Albert J. Bredenoord

In eosinophilic esophagitis (EoE), the esophageal barrier integrity is impaired. Integrity can be assessed with different techniques. To assess the correlations between esophageal eosinophilia and various measures of mucosal integrity and to evaluate whether endoscopic impedance measurements can predict disease activity, endoscopies and mucosal integrity measurements were performed in adult EoE patients with active disease (≥15 eosinophils/high-power field) at baseline ( n = 32) and after fluticasone ( n = 15) and elemental dietary treatment ( n = 14) and in controls ( n = 19). Mucosal integrity was evaluated during endoscopy using electrical tissue spectroscopy (ETIS) measuring mucosal impedance and transepithelial electrical resistance (TER) and transepithelial molecule-flux through biopsy specimens in Ussing chambers. We included 61 measurements; 32 of patients at baseline and 29 after treatment, 3 patients dropped out. After treatment, 20 patients were in remission (≤15 eosinophils/high-power field) and these measurements were compared with 41 measurements of patients with active disease (at baseline or after failed treatment). All four mucosal integrity measures showed significant impairment in active EoE compared with remission. Eosinophilia was negatively correlated with ETIS and TER and positively with transepithelial molecule flux ( P ≤ 0.001). The optimal ETIS cutoff to predict disease activity was 6,000 Ω·m with a sensitivity of 79% [95% confidence interval (CI) 54–94%], specificity of 84% (95% CI 69–94%), positive predictive values of 89% (95% CI 77–95%) and negative predictive values of 71% (95% CI 54–84%). In EoE patients, markers of mucosal integrity correlate with esophageal eosinophilia. Additionally, endoscopic mucosal impedance measurements can predict disease activity. NEW & NOTEWORTHY In adult patients with eosinophilic esophagitis (EoE), the mucosal integrity, measured by making use of four different parameters, correlates strongly with esophageal eosinophilia. The accuracy of endoscopically measured mucosal impedance to distinguish active disease from remission was acceptable with moderate specificity and sensitivity. Mucosal impedance measurements can predict disease activity in adult EoE patients.


Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 773
Author(s):  
Jacob P. Veenstra ◽  
Bhaskar Vemu ◽  
Restituto Tocmo ◽  
Mirielle C. Nauman ◽  
Jeremy J. Johnson

Rosemary extract (RE) is an approved food preservative in the European Union and contains dietary phytochemicals that are beneficial for gastrointestinal health. This study investigated the effects of RE on dextran sodium sulfate (DSS)-induced colitis and also determined the pharmacokinetics of dietary phytochemicals administered to mice via oral gavage. Individual components of rosemary extract were separated and identified by LC–MS/MS. The pharmacokinetics of two major diterpenes from RE, carnosic acid (CA) and carnosol (CL), administered to mice via oral gavage were determined. Then, the effect of RE pre-treatment on the disease activity index (DAI) of DSS-induced colitis in mice was investigated. The study determined that 100 mg/kg RE significantly improved DAI in DSS-induced colitis compared to negative control. Sestrin 2 protein expression, which increased with DSS exposure, was reduced with RE treatment. Intestinal barrier integrity was also shown to improve via fluorescein isothiocyanate (FITC)–dextran administration and Western blot of zonula occludens-1 (ZO-1), a tight junction protein. Rosemary extract was able to improve the DAI of DSS-induced colitis in mice at a daily dose of 100 mg/kg and showed improvement in the intestinal barrier integrity. This study suggests that RE can be an effective preventative agent against IBD.


2014 ◽  
Vol 133 (2) ◽  
pp. AB261
Author(s):  
Cristina Jimenez-Aponte ◽  
Jose Torres-Silva ◽  
Eric Gonzalez-Hernandez ◽  
Liza Gonzalez-Benitez ◽  
Mairim Wiscovich-Torres ◽  
...  

Dysphagia ◽  
2018 ◽  
Vol 34 (1) ◽  
pp. 138-144 ◽  
Author(s):  
Kimberly Johnson ◽  
Vivek Iyer ◽  
David Katzka ◽  
Karthik Ravi ◽  
Ryan Lennon ◽  
...  

2016 ◽  
Vol 150 (4) ◽  
pp. S671
Author(s):  
Kelly Whelan ◽  
Veronique Giroux ◽  
Jamie Merves ◽  
Bridget Godwin ◽  
Joanne C. Masterson ◽  
...  

2018 ◽  
Vol 141 (2) ◽  
pp. AB276
Author(s):  
Mats W. Johansson ◽  
Michael D. Evans ◽  
Elizabeth McKernan ◽  
Paul S. Fichtinger ◽  
Evelyn L. Angulo ◽  
...  

2020 ◽  
Vol 158 (6) ◽  
pp. S-831-S-832 ◽  
Author(s):  
Nicole C. Chang ◽  
Soha Raja ◽  
Renee Betancourt ◽  
Cara Randall ◽  
Staci Keene ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document